DIRS.INFO The most relevant business & tech news

☆ How Trump's selection of RFK Jr. as HHS secretary could impact the pharma sector
▼ + stars: | 2024-11-15 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailHow Trump's selection of RFK Jr. as HHS secretary could impact the pharma sectorJared Holz, healthcare sector strategist at Mizuho Securities America, and CNBC's Angelica Peebles join 'Power Lunch' discuss pharma stocks' reaction to Robert F. Kennedy Jr.'s appointment to lead the Department of Health and Human Services, what the incoming administration could mean for regulation in the sector, and more.

Persons: Jared Holz, Angelica Peebles, Robert F, Kennedy Jr Organizations: RFK Jr, pharma, Mizuho Securities America, Department of Health, Human Services

☆ Watch CNBC's full interview with Don Peebles, CEO and chairman of The Peebles Coporation
▼ + stars: | 2024-11-11 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with Don Peebles, CEO and chairman of The Peebles CoporationDon Peebles, The Peebles Corporation chairman and CEO, joins CNBC's 'Power Lunch' to discuss his expectations for the Trump administration, the impact to markets, and more.

Persons: Don Peebles, The Peebles, Trump Organizations: The, The Peebles Corporation

☆ Eli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantastic
▼ + stars: | 2024-10-30 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO David Ricks on Q3 results: The underlying growth story is fantasticEli Lilly CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, which reported third-quarter adjusted profit and revenue that missed expectations, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro, why the company is slashing its full-year adjusted profit guidance, and more.

Persons: Eli Lilly, David Ricks

Ian Read, chairman and chief executive officer of Pfizer Inc., gestures as he speaks during a panel session at the World Economic Forum (WEF) in Davos, Switzerland, on Tuesday, Jan. 17, 2017. Activist Starboard Value accused Pfizer of threatening litigation against the company's former CEO and CFO in order to get them to break ranks with the investor's nascent turnaround campaign at the pharmaceutical giant. Pfizer shares slipped overnight as news of the two executive's breakaway emerged, and opened down roughly 2.5% in Thursday morning trading. Starboard's Smith said that when the activist approached the two executives, both expressed "concerns" about Pfizer's direction under Bourla and offered to help Starboard in its turnaround campaign. Starboard's Smith and Bourla are slated to meet in person next week, Smith said, confirming earlier reports.

Persons: Ian Read, Pfizer, Jeff Smith, Frank D'Amelio's, Smith, Albert Bourla, Starboard's Smith Organizations: Pfizer Inc, Economic, Pfizer Locations: Davos, Switzerland

☆ Activist Starboard Value has $1 billion Pfizer stake, taps former executives for help, sources say
▼ + stars: | 2024-10-07 | by ( Rohan Goswami | In Rohangoswamicnbc | ) www.cnbc.com time to read: +2 min

Activist investor Starboard Value has a roughly $1 billion stake in pharmaceutical giant Pfizer and is seeking to mount a turnaround at the struggling company, according to people familiar with the matter. Starboard believes that Pfizer's current leadership, under CEO Albert Bourla, has stepped away from historically disciplined cost structure and investment in novel drugs. One particularly concerning example to Starboard was Pfizer's acquisition of Global Blood Therapeutics. Pfizer pulled a drug for sickle cell disease it got just two years ago via the roughly $5 billion acquisition. Still, more than $100 billion in shareholder value has evaporated since the Covid-19 pandemic faded largely into the rearview mirror.

Persons: Ian Read, Frank D'Amelio, Albert Bourla, Oxbryta, Read, Jeff Smith, Angelica Peebles Organizations: Pfizer, Blood Therapeutics, Autodesk, Street

☆ Eli Lilly CEO: We have 11 pipeline projects in obesity
▼ + stars: | 2024-10-02 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly CEO: We have 11 pipeline projects in obesityCNBC's Angelica Peebles joins 'Squawk on the Street' to report on Eli Lilly's new investment in a new $4.5 billion research and development center.

Persons: Eli Lilly, CNBC's Angelica Peebles, Eli Lilly's

☆ Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
▼ + stars: | 2024-10-02 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +2 min

Eli Lilly will spend $4.5 billion to build a center aimed at finding better ways to manufacture its medicines. The facility, called the Lilly Medicine Foundry, will house development of new manufacturing methods with an eye toward efficiency. It's a strategy that's already paying off with Lilly's obesity and weight loss drugs Mounjaro and Zepbound, and Lilly wants it to propel the rest of its pipeline. Lilly says the facility will be the first of its kind to combine research and production in a single location. It will be near a $9 billion manufacturing complex Lilly is building in Lebanon, Indiana, to produce pharmaceutical ingredients like tirzepatide, the active ingredient in Mounjaro and Zepbound.

Persons: Eli Lilly, Mounjaro, Lilly, David Ricks, –, Dan Skovronsky Organizations: Lilly, Foundry, Indianapolis, Novo Nordisk's Ozempic Locations: Indianapolis, Lebanon , Indiana, tirzepatide

☆ Bristol Myers Squibb stock rises following FDA approval of its schizophrenia drug
▼ + stars: | 2024-09-27 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBristol Myers Squibb stock rises following FDA approval of its schizophrenia drugCNBC's Angelica Peebles joins 'Fast Money' to report on Bristol Myers Squibb's stock rise following FDA approval of Cobenfy for treating schizophrenia in adults.

Persons: Angelica Peebles Organizations: Bristol Myers Squibb, Bristol Myers

☆ How rate cuts impact the housing market
▼ + stars: | 2024-09-26 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailHow rate cuts impact the housing marketDon Peebles, Peebles Corp chair and CEO, joins 'Power Lunch' to discuss Peebles' thoughts on the Federal Reserve's moves, why they may need to do more, and if the economy needs a series of bigger rate cuts still.

Persons: Don, Peebles Organizations: Peebles Corp, Federal Locations: Don Peebles, Peebles

☆ Novo Nordisk CEO testifies before Senate on weight loss drug prices
▼ + stars: | 2024-09-24 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk CEO testifies before Senate on weight loss drug pricesCNBC's Angelica Peebles reports on Novo Nordisk's testimony before the Senate Health, Education, Labor, and Pensions Committee.

Persons: Angelica Peebles, Novo Organizations: Novo Nordisk, Health, Education, Labor, Pensions

☆ Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
▼ + stars: | 2024-09-16 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +9 min

watch nowDrugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough. That can allow the treatment to deliver radiation to cancer cells and spare the rest of the body from the level of damage that comes with many cancer drugs. For Pluvicto, patients come in once every six weeks for up to six treatments. One opportunity Bristol Myers Squibb sees is combining radiopharmaceuticals with existing cancer drugs like immunotherapy, said Robert Plenge, Bristol's chief research officer. But she thinks the technology will become an important part of cancer drugs in the next decade.

Persons: Eli Lilly, They've, Michael Schmidt, Schmidt, Franco Origlia, Jacob Van Naarden, Eli Lilly's, Lilly, Biopharma, Van Naarden, Radiopharmaceuticals, Bristol Myers, Ben Hickey, RayzeBio, Hickey, Victor Bulto, Bulto, Timothy Korytko, Ronald Coy, Sharon, Ronald Coy Ronald Coy, Coy, who's, Coy hasn't, she's, we've, Eli Lilly's Van Naarden, Bristol Myers Squibb, Robert Plenge, Susan Galbraith, Galbraith Organizations: Bristol Myers Squibb, AstraZeneca, Guggenheim Securities, Novartis, NSA, Pharmaceutical, Bassett Healthcare Network, Bristol, Fusion Pharmaceuticals, Guggenheim Locations: Aedea Rome, Italy, radiopharmaceuticals, Swiss, FactSet, Bristol, Indiana, U.S, New York, Bassett

☆ Nuveen's Saira Malik explains why she's concerned a recession could be coming
▼ + stars: | 2024-09-16 | by ( Bob Pisani | Angelica Peebles | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNuveen's Saira Malik explains why she's concerned a recession could be comingSaira Malik, president of Nuveen Equities and Fixed Income and CIO, joins CNBC's Bob Pisani at Future Proof 2024 to discuss her outlook for the U.S. economy and what signals could point to an upcoming recession.

Persons: Saira Malik, she's, Bob Pisani Locations: U.S

☆ Former Cornell student gets 21 months in prison for posting violent threats to Jewish students
▼ + stars: | 2024-08-12 | by ( Https | Media-Cldnry.S-Nbcnews.Com Image Upload Newscms Ap-Live-Blog-Byline-Image.Png | The Associated Press | ) www.nbcnews.com time to read: +1 min

SYRACUSE, N.Y. — A former Cornell University student arrested for posting statements threatening violence against Jewish people on campus last fall after the start of the war in Gaza was sentenced Monday to 21 months in prison. Patrick Dai, of suburban Rochester, New York, was accused by federal officials in October of posting anonymous threats to shoot and stab Jewish people on a Greek life forum. The threats came during a spike in antisemitic and anti-Muslim rhetoric related to the war and rattled Jewish students on the upstate New York campus. Dai pleaded guilty in April to posting threats to kill or injure another person using interstate communications. He was sentenced in federal court to 21 months in prison and three years of supervised release by Judge Brenda Sannes, according to federal prosecutors.

Persons: —, Patrick Dai, Dai, Brenda Sannes, Dai “, Dai’s, Lisa Peebles, ” Peebles Organizations: Cornell University, Israel, Ivy League Locations: SYRACUSE, N.Y, Gaza, Rochester , New York, New York, Israel, Ithaca , New York

☆ Tim Walz was the most 'do no harm' candidate, says Libby Cantrill on Harris' VP selection
▼ + stars: | 2024-08-06 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTim Walz was the most 'do no harm' candidate, says Libby Cantrill on Harris' VP selectionDon Peebles, CEO and chairman of the Peebles Corporation, and Libby Cantrill, PIMCO’s head of public policy, join 'The Exchange' to discuss Vice President's potential vice president pick for the upcoming presidential election.

Persons: Tim Walz, Libby Cantrill, Harris, Don Peebles Organizations: Peebles Corporation

☆ How weight loss drugs are driving big gains for pharmaceutical stocks
▼ + stars: | 2024-08-02 | by ( Dominic Chu | Angelica Peebles | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailHow weight loss drugs are driving big gains for pharmaceutical stocksCNBC's Dominic Chu and Angelica Peebles discuss how the boom in weight loss drugs has sent the price of pharmaceutical stocks soaring, and what these companies could be developing next to keep the revenue flowing.

Persons: Dominic Chu, Angelica Peebles

☆ Pfizer's weight loss pill may enter regulatory studies next year, says CEO Albert Bourla
▼ + stars: | 2024-07-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer's weight loss pill may enter regulatory studies next year, says CEO Albert BourlaCNBC's Angelica Peebles interviews Pfizer's CEO Albert Bourla to discuss the company's earnings, expectations for its new weight loss drug, and more.

Persons: Albert Bourla CNBC's Angelica Peebles, Albert Bourla

☆ Medicare set to unveil its negotiated drug prices
▼ + stars: | 2024-07-25 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMedicare set to unveil its negotiated drug pricesCNBC’s Angelica Peebles joins 'Power Lunch' to discuss Medicare's unveiling of its negotiated drug prices.

Persons: Angelica Peebles

☆ AstraZeneca CEO on revenue beat
▼ + stars: | 2024-07-25 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAstraZeneca CEO on revenue beatAstraZeneca CEO Pascal Soriot joins 'Squawk on the Street' to discuss the company's quarterly earnings results, its goal to double sales by 2030, and its Farxiga drug.

Persons: Pascal Soriot Organizations: AstraZeneca

☆ Novartis expects 'strong momentum' going into second half, says CEO Vasant Narasimhan
▼ + stars: | 2024-07-18 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovartis expects 'strong momentum' going into second half, says CEO Vasant NarasimhanVasant Narasimhan, Novartis CEO, joins CNBC's Angelica Peebles on 'The Exchange' to discuss Q2 earnings, reception of its prostate cancer drug, and more.

Persons: Vasant Narasimhan Vasant Narasimhan, Angelica Peebles Organizations: Novartis

☆ Pfizer advances development of once-daily formulation of oral weight loss pill
▼ + stars: | 2024-07-11 | by ( Angelica Peebles | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer advances development of once-daily formulation of oral weight loss pillCNBC's Angelica Peebles joins 'Squawk Box' with the latest news from Pfizer.

Persons: Angelica Peebles Organizations: Pfizer

☆ FTC reportedly plans to sue the three largest pharmacy benefit managers over insulin prices
▼ + stars: | 2024-07-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFTC reportedly plans to sue the three largest pharmacy benefit managers over insulin pricesCNBC's Angelica Peebles joins 'Power Lunch' to discuss reports that the FTC is threatening to sue the three largest pharmacy benefit managers over insulin prices.

Persons: Angelica Peebles Organizations: FTC

☆ Alnylam CEO on what is next for heart disease drug
▼ + stars: | 2024-06-24 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailAlnylam CEO on what is next for heart disease drugCNBC's Angelica Peebles and Yvonne Greenstreet, Alnylam CEO, joins 'Fast Money' to talk the companies latest heart condition drug data and what the path to approval looks like.

Persons: Angelica Peebles, Yvonne Greenstreet

☆ Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
▼ + stars: | 2024-06-20 | by ( Angelica Peebles | In Angelicapeebles | ) www.cnbc.com time to read: +3 min

Gilead 's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday. The results bring Gilead one step closer to introducing a new form of pre-exposure prophylaxis, or PrEP, and broadening its HIV business. If those results are positive, the company could bring lenacapavir for PrEP to market as soon as late 2025. RBC Capital Markets analyst Brian Abrahams expects Gilead's shot will significantly increase the number of people interested in preventive HIV medicine. In its statement disclosing the lenacapavir trial results Thursday, Gilead said it plans to share an update on how it plans to address access in such countries where people suffer high incidence rates of HIV.

Persons: Gilead, Jared Baeten, Gilead's Truvada, Bruce Richman, Tim Oliver, they'd, Brian Abrahams, Gilead's, — CNBC's Leanne Miller Organizations: Food and Drug Administration, PrEP, Centers for Disease Control, Prevention, Health, FDA, RBC Capital Locations: U.S, New York

☆ Watch CNBC's full interview with economists and experts' views on Fed decision
▼ + stars: | 2024-06-11 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailWatch CNBC's full interview with economists and experts' views on Fed decisionDon Peebles, Peebles Corporation CEO and chairman; William Lee, Milken Institute chief economist; Julia Coronado, MarcroPolicy Perspectives founder; David Zervos, Jefferies chief market strategist; Claudia Sahm, New Century Advisors chief economist; and Paul McCulley, Pacific Investment Management Co. former chief economist, join 'Power Lunch to participate in a mock Fed board.

Persons: Don Peebles, William Lee, Julia Coronado, David Zervos, Claudia Sahm, Paul McCulley Organizations: Peebles Corporation, Milken Institute, MarcroPolicy, Jefferies, Claudia Sahm , New Century Advisors, Pacific Investment Management Co Locations: Claudia Sahm ,

☆ FDA advisers say Eli Lilly's Alzheimer's treatment is effective
▼ + stars: | 2024-06-10 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFDA advisers say Eli Lilly's Alzheimer's treatment is effectiveCNBC's Angelica Peebles joins 'Closing Bell' to discuss the FDA's advisers vote on Eli Lilly's Alzheimer's drug.

Persons: Eli Lilly's, Angelica Peebles

Search resuls for: "Peebles"

25 mentions found